Evidence map›Paper›PMID 36504556›Full record

Trial reportWorld journal of gastroenterology2022

Randomized controlled trial to evaluate the efficacy and safety of fexuprazan compared with esomeprazole in erosive esophagitis.

Kang Nyeong Lee, Oh Young Lee, Hoon Jai Chun, Jin Il Kim, Sung Kook Kim, Sang Woo Lee, Kyung Sik Park, Kook Lae Lee, Suck Chei Choi, Jae-Young Jang and 16 more

Registry-linked trialOpen access · hybridAbstract readRandomized Controlled Trial
PubMed Full text at PMC Publisher
In one paragraph

Trial report in World journal of gastroenterology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT07326904 (A Multi-Center, Randomized, Open-Label Study to Evaluate Symptom Relief and Safety After Using Fexuprazan 40 Mg Compared to Esomeprazole 40 Mg in Patients With Gastroesophageal Reflux Disease), which is not on this map. Cited by 38 papers, 6 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
38citing papers in PubMed, 6 pooled it
7.9field-weighted citation impact, top 2% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT07326904 phase3completednot on this mapstarted 2024, after this paper: background citation

A Multi-Center, Randomized, Open-Label Study to Evaluate Symptom Relief and Safety After Using Fexuprazan 40 Mg Compared to Esomeprazole 40 Mg in Patients With Gastroesophageal Reflux Disease (GERD)

TypeinterventionalSponsorIndonesia UniversityRan2024 to 2024Enrolled145ConditionsGastro Oesophageal Reflux DiseaseArmsFexuprazan, Esomeprazole
3 · Its place in the literature

Who cites it

38 citing papers in PubMed, 6 syntheses or guidelines pooled it, 53 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Pooled it
  5. Pooled it
  6. Pooled it
  7. Trial
  8. Trial
  9. Efficacy and safety of fexuprazan in patients with symptoms and signs of laryngopharyngeal reflux disease: a randomized clinical trial.European archives of oto-rhino-laryngology : official journal of the European Federation of Oto-Rhino-Laryngological Societies (EUFOS) : affiliated with the German Society for Oto-Rhino-Laryngology - Head and Neck Surgery · 2024
    Trial
  10. Review
  11. Article
  12. Article
  13. Review
  14. Article
  15. Observational
  16. Article
  17. Review
  18. Nonsteroidal Anti-Inflammatory Drug-Induced Peptic Ulcer Disease.The Korean journal of helicobacter and upper gastrointestinal research · 2025
    Review
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

26 authors at 19 institutions in 1 country.

Kang Nyeong LeeDepartment of Internal Medicine, Hanyang University College of Medicine, Seoul 04763, South Korea.
Oh Young LeeDepartment of Internal Medicine, Hanyang University College of Medicine, Seoul 04763, South Korea. leeoy@hanyang.ac.kr.
Hoon Jai ChunDepartment of Internal Medicine, Korea University Anam Hospital, Seoul 02841, South Korea.
Jin Il KimDepartment of Internal Medicine, The Catholic University of Korea, Yeouido ST. Mary's Hospital, Seoul 07260, South Korea.
Sung Kook KimDepartment of Internal Medicine, Kyungpook National University Hospital, Daegu 41944, South Korea.
Sang Woo LeeDepartment of Internal Medicine, Korea University Ansan Hospital, Ansan-si 15355, South Korea.
Kyung Sik ParkDepartment of Internal Medicine, Keimyung University Dongsan Hospital, Daegu 42601, South Korea.
Kook Lae LeeDepartment of Internal Medicine, Seoul Metropolitan Government Seoul National University Boramae Medical Center, Seoul 07061, South Korea.
Suck Chei ChoiDepartment of Internal Medicine, Wonkwang University Hospital, Iksan 54538, South Korea.
Jae-Young JangDepartment of Internal Medicine, KyungHee University Medical Center, Seoul 02447, South Korea.
Gwang Ha KimDepartment of Internal Medicine, Pusan National University School of Medicine and Biomedical Research Institute, Pusan National University Hospital, Busan 47241, South Korea.
In-Kyung SungDepartment of Internal Medicine, KKonkuk University Medical Center, Seoul 05030, South Korea.
Moo In ParkDepartment of Internal Medicine, Kosin University Gaspel Hospital, Busan 49267, South Korea.
Joong Goo KwonDepartment of Internal Medicine, Daegu Catholic University Medical Center, Daegu 42471, South Korea.
Nayoung KimDepartment of Internal Medicine, Seoul National University Bundang Hospital, Seongnam-si 13620, Gyeonggi-do, South Korea.
Jae Jun KimDepartment of Internal Medicine, Samsung Medical Center, Seoul 06351, South Korea.
Soo Teik LeeDepartment of Internal Medicine, Chonbuk National University Hospital, Jeonju-si 54907, South Korea.
Hyun Soo KimDepartment of Internal Medicine, Chonnam National University Hospital, Gwangju 61469, South Korea.
Ki Bae KimDepartment of Internal medicine, Chungbuk National University School of Medicine, Cheong Ju 28644, South Korea.
Yong Chan LeeDepartment of Internal Medicine, Severance Hospital, Seoul 03722, South Korea.
Myung-Gyu ChoiDepartment of Internal Medicine, The Catholic University of Korea, Seoul ST. Mary's Hospital, Seoul 06591, South Korea.
Joon Seong LeeDigestive Disease Center, Soonchunhyang University College of Medicine, Seoul 04401, South Korea.
Hwoon-Yong JungDepartment of Internal Medicine, Asan Medical Center, Seoul 05505, South Korea.
Kwang Jae LeeDepartment of Gastroenterology, Ajou University School of Medicine, Suwon 16499, South Korea.
Jie-Hyun KimDepartment of Internal Medicine, Gangnam Severance Hospital, Yonsei University College of Medicine, Seoul 06273, South Korea.
Hyunsoo ChungDepartment of Internal Medicine, Seoul National University Hospital, Seoul 03080, South Korea.
Catholic University of Korea · KRAjou University · KRAnsan University · KRChonnam National University Hospital · KRChungbuk National University · KRDaegu Catholic University Medical Center · KRGangnam Severance Hospital · KRJeonbuk National University Hospital · KRKorea University Medical Center · KRKyung Hee University Medical Center · KRKyungpook National University Hospital · KRSamsung Medical Center · KRSeoul Metropolitan Government · KRSeoul National University · KRSeoul National University Bundang Hospital · KRSeoul National University Hospital · KRSeverance Hospital · KRSoonchunhyang University · KRWonkwang University · KR

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundFexuprazan, a novel potassium-competitive acid blocker, reversibly suppresses the K

aimTo compare fexuprazan to esomeprazole and establish its efficacy and safety in patients with erosive esophagitis (EE).

methodsKorean adult patients with endoscopically confirmed EE were randomized 1:1 to receive fexuprazan 40 mg or esomeprazole 40 mg once daily for eight weeks. The primary endpoint was the proportion of patients with healed EE confirmed by endoscopy at week 8. The secondary endpoints included the healing rate of EE at week 4, symptom response, and quality of life assessment. Safety profiles and serum gastrin levels were compared between the groups.

resultsOf the 263 randomized, 218 completed the study per protocol (fexuprazan 40 mg,

conclusionFexuprazan 40 mg is non-inferior to esomeprazole 40 mg in EE healing at week 8. We suggest that fexuprazan is an alternative promising treatment option to PPIs for patients with EE.

Indexed as

Drug-Related Side Effects and Adverse ReactionsEsophagitisPeptic UlcerAdultAminesEsomeprazoleGastrinsH(+)-K(+)-Exchanging ATPaseHumansPyrrolesQuality of LifeAminesEsomeprazolefexuprazanGastrinsH(+)-K(+)-Exchanging ATPasePyrrolesEsophagitisGastroesophageal refluxHeartburnProton pump inhibitorsQuality of life

Identifiers

PMID36504556
PMCPMC9730436
OpenAlexW4310122302

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.